



News Release

May 23, 2022
Maruho Co., Ltd.

Maruho Launches Primary Axillary Hyperhidrosis Treatment “Rapifort® Wipes 2.5%” in Japan

Osaka (Japan), May 23, 2022 – Maruho Co., Ltd. (“Maruho”, Head Office: Osaka, Japan, President and CEO: Atsushi Sugita) announces that it has launched "Rapifort® Wipes 2.5%" (Japanese Accepted Name (JAN): glycopyrronium tosilate hydrate, hereinafter referred to as "the product"), for the treatment of primary axillary hyperhidrosis in Japan.

Primary axillary hyperhidrosis is a disease that causes excessive underarm sweating with no clear cause that interferes with daily life activities¹.

The prevalence in Japan is 5.75%², about 1 in 20 people have been reported to have primary axillary hyperhidrosis. In Japan, there are only a limited number of therapeutic agents covered by insurance indicated for the treatment of primary axillary hyperhidrosis, and new treatment options are needed.

The product is a wipe formulation with a partial modification of the prescription of a topical agent developed by Dermira, Inc.* in the US (not approved in Japan). The active ingredient, glycopyrronium tosilate hydrate, reduces sweat production by blocking the activation of acetylcholine receptors in sweat glands. Sweat is suppressed by applying the drug solution to both underarms once a day using one sheet of non-woven fabric enclosed in one packet. Since it is a single-use wipe formulation, it can be used easily and hygienically.

Specializing in dermatology, Maruho hopes that with the proper use of this product it can contribute to improving the quality of life of patients suffering from primary axillary hyperhidrosis.

Product Profile for Rapifort® Wipes 2.5%

Brand Name	Rapifort® Wipes 2.5%
JAN	Glycopyrronium tosilate hydrate
Formulation/Dose	62.5mg of glycopyrronium tosilate hydrate in one packet (2.5g of drug solution)
Indication	Primary axillary hyperhidrosis
Dosage and Administration	Apply the drug solution to both underarms once a day using one sheet of non-woven fabric enclosed in one packet.
NHI Drug Price Standard	One packet 262.00 yen
Date of Approval	January 20, 2022
Date of NHI Price Listing	April 20, 2022
Date of Launch	May 23, 2022
Manufacturer	Maruho Co., Ltd.

References

1. Japanese Dermatological Association Guidelines: Primary Local Hyperhidrosis Practice Guidelines 2015 Revised Edition, The Japanese Journal of Dermatology 2015; 125: 1379-1400
2. Fujimoto T, et al. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis. J Dermatol. 2013; 40: 886–90.

Note

*The rights to the product are currently owned by Journey Medical Corporation.

About Maruho

Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,546 employees (as of the end of September 2021), and net sales were approximately 87.03 billion yen in its fiscal year ended September 30, 2021. Pursuing its long-term corporate vision of “Excellence in Dermatology,” Maruho is striving to improve the health and quality of life of people all over the world.

For more information, please visit <https://www.maruho.co.jp/english/>

Contact Information:

Maruho Co., Ltd.

Corporate Planning Dept. Public Relations Group

Tel: +81-(0)6-6371-8831 Fax: +81-(0)6-6371-8679

Email: kouhou@mii.maruho.co.jp